Loading stock data…
Amphastar Pharmaceuticals, Inc. (AMPH)
$23.18-0.66 (-2.77%)
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $23.18 with a market capitalization of $986M. Wall Street consensus targets $22.50 (6 analysts), implying a -2.9% move over the next 12 months. The stock is currently 21% below its 52-week high of $29.52, remaining 2.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $183.90M↑ | $171.17M↓ | $183.10M↓ | $191.84M↑ | $174.41M |
| Gross Profit | $93.47M↑ | $70.32M↓ | $85.67M↓ | $98.65M↑ | $86.49M |
| Operating Income | $39.73M↑ | $13.63M↓ | $35.61M↑ | $25.32M↓ | $42.18M |
| Net Income | $30.35M↑ | $6.42M↓ | $24.43M↑ | $17.35M↓ | $31.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$986.03M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.72
Beta
Defensive asset. Lower volatility than the S&P 500.
0.92
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.23%
Volume
Today's trading volume
650,129
Recent News
Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?
Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year. Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that...
Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting
Amphastar Pharmaceuticals stock presents a tricky mix for investors, with a steep 3 year share price decline set against valuation checks that now lean cheap on traditional multiples. Over the past 3 years the share price has fallen about 53.6%, which leaves current holders facing a deep drawdown and raises the question of whether the stock has been pushed too far down. Future expectations for Amphastar Pharmaceuticals around the durability of its product portfolio and its ability to convert...
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.